Pacira BioSciences
PCRX
160 hedge funds and large institutions have $2.47B invested in Pacira BioSciences in 2014 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 57 increasing their positions, 47 reducing their positions, and 10 closing their positions.
290% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 10
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
72% more call options, than puts
Call options by funds: $11.1M | Put options by funds: $6.45M
22% more capital invested
Capital invested by funds: $2.02B → $2.47B (+$448M)
21% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 47
21% more funds holding
Funds holding: 132 → 160 (+28)
Top Buyers
| 1 |
MCM
Marsico Capital Management
Denver,
Colorado
|
+$47.2M |
| 2 |
NCGI
Next Century Growth Investors
Plymouth,
Minnesota
|
+$24.3M |
| 3 |
O
OppenheimerFunds
New York
|
+$22M |
| 4 |
CCI
Columbus Circle Investors
|
+$21.2M |
| 5 |
Millennium Management
New York
|
+$16.8M |
Top Sellers
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$39M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$37M |
| 3 |
Bank of New York Mellon
New York
|
-$32.6M |
| 4 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$30.2M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$27.2M |
PCRX Hedge Fund Activity: Q1 2014 in Review
160 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q1 2014, worth a combined $2.47B — up 22% from $2.02B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new PCRX positions and 10 closed out — a net gain of 29 holders — while 57 added to existing stakes and 47 trimmed.
The largest buyer was Marsico Capital Management, adding an estimated $47.2M. The largest seller was AllianceBernstein, cutting an estimated $39M.
- 160 institutional investors held Pacira BioSciences (PCRX) as of Q1 2014, up from 132 in Q4 2013.
- Funds reported $2.47B of Pacira BioSciences stock for Q1 2014, up 22% quarter-over-quarter.
- 39 funds opened new Pacira BioSciences positions in Q1 2014 and 10 closed out, a net change of +29 holders.
- The largest Pacira BioSciences buyer in Q1 2014 was Marsico Capital Management, an estimated $47.2M added.
- The largest Pacira BioSciences seller in Q1 2014 was AllianceBernstein, an estimated $39M sold.
Based on aggregated 13F filings for Q1 2014.